戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  infection, other respiratory, or other (eg, agranulocytosis).
2 lozapine is associated with life-threatening agranulocytosis.
3  cornerstone, but may cause life-threatening agranulocytosis.
4 d reversible neutropenia, but none developed agranulocytosis.
5 ability of 0.7% that a patient would develop agranulocytosis.
6 ating factor (GCSF) in levamisole-associated agranulocytosis.
7 patients with a history of clozapine-induced agranulocytosis.
8 of extrapyramidal side effects but may cause agranulocytosis.
9 remaining life expectancy after detection of agranulocytosis.
10 atment-resistant schizophrenia but can cause agranulocytosis.
11 ence of a causal effect on clozapine-induced agranulocytosis.
12 ping prediction models for clozapine-induced agranulocytosis.
13 ts use is limited by its potential to induce agranulocytosis.
14 ocyte counts with potential life-threatening agranulocytosis.
15  assumed a 20% mortality among patients with agranulocytosis, $30.61 in monitoring costs each week, a
16 dults with any non-chemotherapy drug-induced agranulocytosis (absolute neutrophil count </=0.5 x 10(9
17                                 The rates of agranulocytosis (absolute neutrophil count [ANC] < 500 x
18 ich they attest to understanding the risk of agranulocytosis and commit to performing required blood
19 t (albeit rare) adverse reactions, including agranulocytosis and hepatotoxicity.
20 hat can cause adverse side effects including agranulocytosis and liver damage.
21 ults could be useful for antithyroid-induced agranulocytosis and potentially for agranulocytosis caus
22 erases (two events in two patients, one with agranulocytosis), and decline in neurological functionin
23 One patient treated with clozapine developed agranulocytosis, and another developed eosinophilia; bot
24 utrophil counts below 0.5 x 10(9)/L, two had agranulocytosis, and four had recurrent infections.
25 sisting mainly of isolated thrombocytopenia, agranulocytosis, and leukopenia.
26 t possible to predict or prevent the risk of agranulocytosis, and the mechanisms are unknown but like
27 to-norclozapine ratio) and clozapine-induced agranulocytosis, applying the conditional false discover
28                         To avoid one case of agranulocytosis, based on the possible risk reduction if
29 the drug adverse reaction, clozapine-induced agranulocytosis (CA), is associated with different HLA t
30 dy on two separate subject sets (in total 42 agranulocytosis cases and 1,208 Graves' disease controls
31                                              Agranulocytosis caused by levamisole exposure through co
32 -induced agranulocytosis and potentially for agranulocytosis caused by other chemicals.
33 nalysis with data from the Clozapine-Induced Agranulocytosis Consortium (up to 163 cases and 7970 con
34                                              Agranulocytosis developed in three patients in the cloza
35 I because of the observation of drug-induced agranulocytosis (DIAG) in two subjects.
36  not evidence-based because the incidence of agranulocytosis does not exceed that of conventional ant
37                        For clozapine-induced agranulocytosis, five loci were identified after conditi
38 d by utilizing cumulative incidence rates of agranulocytosis from a recent study with a large sample
39 s curtailed by the risk of clozapine-induced agranulocytosis/granulocytopenia (CIAG), a severe advers
40 f clozapine metabolism and clozapine-induced agranulocytosis have identified few genetic loci.
41 serious adverse events with deferiprone were agranulocytosis in 2 participants and neutropenia in 3 p
42 actory schizophrenia, causes neutropenia and agranulocytosis in 3 and 0.8% of patients, respectively.
43 nts associated with antithyroid drug-induced agranulocytosis in a white European population.
44 fective because of the very low incidence of agranulocytosis in the later periods.
45  Hong Kong have shown an association between agranulocytosis induced by antithyroid drugs and the HLA
46                                              Agranulocytosis induced by non-chemotherapy drugs in gen
47                                 Drug-induced agranulocytosis is a potentially life-threatening advers
48 pine, although the incidence of drug-induced agranulocytosis is lower than previously expected.
49                                   Late-onset agranulocytosis is rare during treatment with clozapine,
50 sis, a severe combined immunodeficiency with agranulocytosis, lymphopenia, and sensorineural deafness
51                                              Agranulocytosis occurred in 1.2 percent of the patients
52               Three (2%) cases of reversible agranulocytosis occurred in the 193 patients in the safe
53 mptoms, 4 had a rising serum ferritin, 3 had agranulocytosis or neutropenia, 1 had tachycardia, 1 had
54 tment did not induce additional weight gain, agranulocytosis, or seizures compared with clozapine/pla
55 gly associated with antithyroid drug-induced agranulocytosis: rs652888 (OR 4.73, 95% CI 3.00-7.44, p=
56  severely restricted due to hepatoxicity and agranulocytosis side effects associated with its long te
57               The authors describe a case of agranulocytosis that emerged after 19 years of continuou
58                   39 of the 234 patients had agranulocytosis that was induced by antithyroid drugs (t
59 deepened our understanding of the levamisole-agranulocytosis vasculopathy syndrome.
60 cted probability of antithyroid drug-induced agranulocytosis was about 30% (OR 753, 95% CI 105-6812).
61 te European people, antithyroid drug-induced agranulocytosis was associated with HLA-B*27:05 and with
62 0 (3.81-13.96) when antithyroid drug-induced agranulocytosis was compared with population controls (p
63                         The discovery of the agranulocytosis was due to the lifelong white blood cell